Skip to main content
Premium Trial:

Request an Annual Quote

Transgenomic, Amgen Ink Deal to Develop Test for KRAS, NRAS

NEW YORK (GenomeWeb News) – Transgenomic today announced a deal with Amgen to develop a CE-IVD test to screen patients with metastatic colorectal cancer for KRAS and NRAS mutations.

The mutations will be identified with Transgenomic's CE-IVD CRC RAScan kits, which use Surveyor-Wave technology. The test will allow physicians to incorporate tumor mutation status into their treatment decisions.

The Omaha, Neb.-based company said its CLIA laboratory is available to immediately receive patient samples for testing. The CE-IVD test kits will be available in Europe, as well as in the US soon as research use only products.

Financial and other terms of the alliance were not disclosed.